WuXi AppTec (02359) announced its interim results, with net profit attributable to the parent company amounting to approximately 11.08 billion yuan, a year-on-year increase of 33.7%. A dividend of 5.1 yuan per 10 shares will be distributed.

WuXi AppTec (02359) announced its mid-year performance for 2026, with revenue of approximately 28.8975 billion yuan, a year-on-year increase of 38.9%; gross profit of approximately 15.382 billion yuan, a year-on-year increase of 68.8%; net profit attributable to shareholders of the parent company of approximately 11.08 billion yuan, a year-on-year increase of 33.7%; adjusted net profit attributable to shareholders of the parent company of approximately 11.57 billion yuan, a year-on-year increase of 83.2%; and basic earnings per share of 3.8 yuan, with a proposed cash dividend of 5.1 yuan for every 10 shares. Among these, the chemical business achieved revenue of 24.99 billion yuan, a year-on-year increase of 53.3%, primarily benefiting from the stable progress of pipeline molecules into later stages and the gradual release of newly added capacity throughout the year. The testing business realized revenue of 2.48 billion yuan, a year-on-year increase of 31.5%. The biological business generated revenue of 1.39 billion yuan, a year-on-year increase of 11.2%, mainly benefiting from integrated services that enhance the efficiency of global clients through synergy in drug discovery, intra- and inter-regional cooperation, and focus areas. As of the end of June 2026, the company's continuous operations had a backlog of orders amounting to 66.43 billion yuan, a year-on-year increase of 25.2%. The announcement stated that the company continues to focus on its unique integrated CRDMO core business, accelerating global layout and capacity and capability building; seizing customer demand for empowerment, providing efficient and ultimate service to clients, and helping global patients to drive the company's long-term development; deepening refined management and operations to continue improving production and operational efficiency, and enhancing resilience to cope with a complex and changing business environment. Thanks to the greater success of products from multiple clients, as well as the company's unique CRDMO model and excellent management and execution, the company has raised its full-year performance guidance for 2026. It now expects overall revenue for 2026 to be adjusted from 51.353 billion yuan to 58.560.5 billion yuan, with the year-on-year growth rate for continuous operations revenue raised from 18%22% to 35%39%. The company will continue to promote high-quality growth, steadily release scale advantages, refine operational management capabilities, and efficiently address challenges such as the ramp-up of new capacity and exchange rate fluctuations. The company is confident in maintaining a stable and resilient adjusted non-IFRS net profit margin for shareholders of the parent company in 2026. To better meet the growing customer demand, the company is further accelerating its global capacity layout and has initiated the construction of a new base in Changzhou ahead of schedule, with expected capital expenditures raised from 6.57.5 billion yuan to 7.58.5 billion yuan for 2026. With business growth and efficiency improvements, the expected adjusted free cash flow for 2026 has been increased from 10.511.5 billion yuan to 13.514.5 billion yuan.